leisure time -WSS

leisure time

author：leisure time 2025-09-28 09:05:58 - browse：236

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Padmanee Sharma of MD Anderson at center of lawsuit over credit

leisure time

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Diverse clinical trials: Why aren’t we there yet?

New Covid vaccine is recommended for everyone 6 months or older

Telehealth for opioid use disorder is lifesaving

FDA proposes changes to key medical devices approval pathway

Johnson & Johnson sued for allegedly overpaying for workers' drugs

knowledge

leisure time

leisure time

How one medical school became remarkably diverse

Long Covid needs a new name — and a new frame

Walensky prepares to leave CDC — and Congress — behind

Acelyrin, a rare IPO success, stumbles in its first big test

Duchenne breakthrough therapy leaves behind pioneering families

Food makers tried to stack nutrition panel with preferred experts

FDA approval of Sarepta Duchenne genetic therapy gives me hope

IRA could hurt research into orphan drugs for rare diseases

Virginia high school admissions case could be legal follow

Acelyrin, a rare IPO success, stumbles in its first big test

Wikipedia

FDA panel endorses Alnylam’s heart drug — after picking it apart

Top private equity targets in 2023: cardiology, clinical trials, lasers

Gene therapy for Afghan refugees’ infant will be fully covered

How to make the FDA’s new prescription one

Global cancer cases to surge 77% by 2050, WHO report says

White House touts steps to stem shortages of cancer treatments

focus

hotspot

leisure time

focus